Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

This 14-month, phase 2, double-blind, randomised, placebo-controlled clinical trial found that lixisenatide, a glucagon-like peptide-1 receptor agonist-1 antagonist, can improve motor symptoms. 10 The ...

Clinicians usually prescribe metformin, a sulfonylurea, or a thiazolidinedione as initial drug therapy for type 2 diabetes. Researchers compared these options in a double-blind, randomized trial ...

Lixisenatide is under clinical development by Sanofi and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition ...

Medically reviewed by Femi Aremu, PharmD Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs used to ...